Loading clinical trials...
Loading clinical trials...
Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
Conditions
Interventions
Ibrutinib Combined With Rituximab
Start Date
October 1, 2021
Primary Completion Date
April 1, 2022
Completion Date
July 1, 2025
Last Updated
August 6, 2021
NCT05139017
NCT06043011
NCT06528301
NCT07255963
NCT05940272
NCT06830031
Lead Sponsor
Chinese Academy of Medical Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions